<?xml version="1.0" encoding="UTF-8"?>
<ref id="B13-vaccines-08-00174">
 <label>13.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tsai</surname>
    <given-names>W.-Y.</given-names>
   </name>
   <name>
    <surname>Lai</surname>
    <given-names>C.-Y.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>Y.-C.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>H.-E.</given-names>
   </name>
   <name>
    <surname>Edwards</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Jumnainsong</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Kliks</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Halstead</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Mongkolsapaya</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Screaton</surname>
    <given-names>G.R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection</article-title>
  <source>J. Virol.</source>
  <year>2013</year>
  <volume>87</volume>
  <fpage>12562</fpage>
  <lpage>12575</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00871-13</pub-id>
  <?supplied-pmid 24027331?>
  <pub-id pub-id-type="pmid">24027331</pub-id>
 </element-citation>
</ref>
